Introduction
============

Esophageal cancer (EC) is the eighth most common cancer globally and has the sixth poorest survival rate.[@b1-ott-11-651] The worldwide incidence of EC has been increasing for several decades for reasons that are not entirely clear but may be related to the increasing prevalence of risk factors such as smoking, alcohol intake, and obesity.[@b2-ott-11-651],[@b3-ott-11-651] Esophageal squamous cell carcinoma (ESCC) is the predominant histological type worldwide, with the majority of ESCCs occurring in Asia and southeastern Africa.[@b4-ott-11-651] However, in Western Europe and northern America, there is a preponderance of esophageal adenocarcinoma (EAC).[@b5-ott-11-651] Despite the development of adequate treatments, including endoscopic resection, surgical resection, chemotherapy, and radiotherapy, treatment outcomes are far from satisfactory, and the 5-year survival rates are \~15%--25%.[@b2-ott-11-651],[@b6-ott-11-651] Due to the insidious early symptoms of EC and the lack of effective screening techniques, most patients are diagnosed in an advanced stage.[@b7-ott-11-651] Therefore, more effective and robust biomarkers are in great demand for the early screening, diagnosis, and prognosis of EC.

EC carcinogenesis is a complex and multifactorial process that includes the accumulation of multiple genetic and epigenetic changes. The precursor lesions for EAC and ESCC are Barrett's esophagus (BE) and dysplasia, respectively. A minority of individuals with precancerous lesions will develop EC through a progression sequence.[@b8-ott-11-651] Encompassing complicated aspects of cancer development, epigenetic modification is considered to have a crucial role in the carcinogenesis of EC.[@b9-ott-11-651] As one of the most important epigenetic alterations, abnormal DNA methylation in the promoter region induces transcriptional silencing of tumor suppressor genes (TSGs) and plays an important role in the progression of several cancers, such as cervical cancer,[@b10-ott-11-651] hepatocellular carcinoma,[@b11-ott-11-651] and head and neck squamous cell carcinoma.[@b12-ott-11-651] In addition, aberrant methylation has been shown to occur early in the progression of precancerous lesions to EC.[@b13-ott-11-651] Moreover, due to precise and convenient methods of detection, DNA methylation has become a noninvasive biomarker for the early detection and diagnosis of cancer.[@b14-ott-11-651]

The mutL homolog-1 (*MLH1*) gene on chromosome 3p22.3 is a key component of the DNA mismatch repair (MMR) pathway, which is a system for recognizing and repairing erroneous insertion, deletion, and misincorporation of bases during DNA replication and is critical for maintaining genomic stability.[@b15-ott-11-651] Inactivation of *MLH1* was reported to be a contributing factor in the initiation and development of gastrointestinal cancer exhibiting high-frequency microsatellite instability.[@b16-ott-11-651],[@b17-ott-11-651] Moreover, hypermethylation of the *MLH1* gene promoter was shown to be responsible for the loss of *MLH1* expression in a wide variety of cancers, including lung cancer,[@b18-ott-11-651] colorectal cancer,[@b19-ott-11-651] gastric carcinoma,[@b20-ott-11-651] ovarian cancer,[@b21-ott-11-651] and ECs.[@b22-ott-11-651] However, there were inconsistent results among different studies in assessing the association between *MLH1* promoter methylation and EC. In addition, the role of *MLH1* promoter methylation in EC carcinogenesis and its clinical application for EC diagnosis and prognosis remain less intensely investigated.

Therefore, we carried out a meta-analysis to evaluate the association between *MLH1* promoter methylation and EC risk and its role in EC carcinogenesis. We also determined whether *MLH1* promoter methylation was correlated with clinicopathological characteristics and overall survival (OS) of EC patients. In addition, we assessed the diagnostic value of *MLH1* methylation for EC.

Materials and methods
=====================

Literature search
-----------------

PubMed, Google Scholar, Web of Science, Embase, and China National Knowledge Infrastructure, and Wanfang databases were systematically searched to find eligible studies without language restrictions published prior to May 5, 2017. We used the following key words and search terms, individually as well as in various combinations: "*MLH1*," "*hMLH1*," "MutL homolog-1," "methylation," "DNA methylation," "promoter methylation," "esophageal carcinoma," "esophagus cancer," "esophageal tumor," and "esophageal malignancy." Furthermore, we manually reviewed the reference lists of the initially identified articles to find more potentially relevant articles.

Selection criteria
------------------

For the studies to be included in the meta-analysis, they had to meet the following criteria: 1) study samples were confirmed by pathology, including ECs, esophageal precancerous lesions (dysplasia or BE), and normal controls; 2) studies that evaluated the methylation frequency of the *MLH1* promoter in the progression of EC carcinogenesis or assessed the association between *MLH1* methylation status and the prognosis of EC patients; 3) studies that were of case--control or cohort designs; and 4) studies that provided sufficient data regarding the methylation frequency of the *MLH1* promoter to enable the calculation of odds ratios (ORs) and 95% CIs or have reported hazard ratios (HRs) and corresponding 95% CIs. If the authors published several articles using the same (or overlapping) data, only the study with the most complete or up-to-date information was included in the meta-analysis.

Data quality assessment
-----------------------

The quality of studies was assessed according to the Newcastle--Ottawa Scale (NOS) criteria.[@b23-ott-11-651] The NOS evaluation system includes three aspects: 1) subject selection: 0--4 points; 2) comparability of subjects: 0--2 points; and 3) clinical outcome: 0--3 points. NOS scores range from 0 to 9, and a score ≥7 indicates a good quality. Only studies with scores ≥7 were included in the analysis.

Data extraction
---------------

Three reviewers (JL, DY, and CCZ) independently extracted relevant data from eligible articles using a standardized form. The following information was extracted: first author, publication year, countries, the ethnicity of subjects, the number of samples, control source, methods to detect *MLH1* methylation, frequency of *MLH1* methylation, HR and the corresponding 95% CI for EC patients with methylated *MLH1*, and clinicopathological characteristics (including age, gender, smoking history, alcohol consumption, tumor location, differentiation grade, tumor stage, lymph node metastasis, distant metastasis, and clinical stage). The three reviewers discussed any discrepancies and eventually reached consensus.

Statistical analyses
--------------------

All the analyses were conducted using Stata statistical software, Version 12.0 (Stata Corporation, College Station, TX, USA). The pooled ORs and corresponding 95% CIs were used to evaluate the strengths of the associations between *MLH1* methylation and the development of EC carcinogenesis, along with clinicopathological features of EC patients. The assessment of potential heterogeneity was quantified based on Cochran's *Q*-tests[@b24-ott-11-651] and *I*-squared (*I*^2^) tests,[@b25-ott-11-651] with statistically significant heterogeneity defined as *P*\<0.05 or *I*^2^\>50%. A random-effects model[@b26-ott-11-651] was used to calculate the pooled OR when significant heterogeneity was observed; otherwise, a fixed-effects model was applied.[@b27-ott-11-651] Subgroup analyses stratified by ethnicity, histology, control source, detection method, sample size, and publication year were performed to detect potential sources of heterogeneity and lower the between-study heterogeneity. We also performed a sensitivity analysis to assess the robustness of the results and determine the influence of individual studies on the pooled results.[@b28-ott-11-651] Publication bias was quantitatively assessed by using Begg's linear regression tests[@b29-ott-11-651] and Begg's rank correlation.[@b30-ott-11-651] HRs with 95% CIs were calculated to evaluate the association between *MLH1* methylation and the prognosis of EC patients. Pooled sensitivity and specificity were used to assess the diagnostic power of *MLH1* methylation test for EC. Moreover, to evaluate the overall accuracy and stability of the diagnostic test, the summary receiver operating characteristic (SROC) curve and the area under the SROC curve (AUC) were also calculated.[@b31-ott-11-651] Fagan plot analysis was performed with 25%, 50%, and 75% pretest probability to assess the diagnostic power of *MLH1* methylation in clinical practice for EC diagnosis.[@b32-ott-11-651] All *P*-values were two-sided, and a *P*-value \<0.05 was considered statistically significant.

Results
=======

Study characteristics
---------------------

[Figure 1](#f1-ott-11-651){ref-type="fig"} presents the strategy for the selection of included studies as well as the final studies included in the meta-analysis. A total of 242 articles were initially retrieved from a search of six databases. After reading the titles and abstracts, 161 duplicate articles were removed, and 42 articles were excluded due to unrelated content. Based on our search criteria, 39 of the remaining articles were retrieved for detailed evaluation. Among these articles, 10 were excluded due to their focus on cell lines or animal trials, and 7 articles were eliminated for having insufficient data on *MLH1* promoter methylation. Finally, 19 articles (including 17 case--control and two cohort studies) fulfilled our inclusion criteria and were included in the meta-analysis.[@b22-ott-11-651],[@b33-ott-11-651]--[@b50-ott-11-651] [Table 1](#t1-ott-11-651){ref-type="table"} presents the basic characteristics of all eligible studies.

Association between *MLH1* promoter methylation and EC carcinogenesis
---------------------------------------------------------------------

With no obvious evidence of heterogeneity between studies (cancer vs controls: *I*^2^=0%, *P*=0.45; cancer vs precancerous lesions: *I*^2^=0%, *P*=0.41; precancerous lesions vs controls: *I*^2^=0%, *P*=0.92), the association between *MLH1* promoter methylation and carcinogenesis of EC was evaluated by using a fixed-effects model. A total of 15 case--control studies, the samples of which collectively included 1,237 ECs and 1,223 normal controls, were included in the current meta-analysis. Our results indicated that the frequency of methylation of the *MLH1* promoter was significantly higher in ECs than in normal controls (OR=8.40, 95% CI =5.75--12.28, *P*\<0.01; [Figure 2A](#f2-ott-11-651){ref-type="fig"}). A subgroup analysis was conducted by ethnicity, histology, control source, detection method, sample size, and publication year. The results of this subgroup analysis showed that *MLH1* hypermethylation was significantly associated with EC in all subgroups ([Table 2](#t2-ott-11-651){ref-type="table"}). Subgroup analysis by ethnicity revealed an OR of 11.90 (95% CI =2.75--51.51, *P*\<0.01) for Caucasian populations and 8.15 (95% CI =5.75--12.08, *P*\<0.01) for Asian populations. The histology subgroup analysis showed that the OR was 8.32 (95% CI =5.64--12.29, *P*\<0.01) for the ESCC subgroup, and it was 9.98 (95% CI =1.83--54.32, *P*\<0.01) for the EAC subgroup. To test the robustness of our results, a sensitivity analysis was performed to determine the influence of an individual study on overall pooled ORs. The omission of individual studies did not significantly change the pooled OR, suggesting that the results were stable and credible ([Figure 3](#f3-ott-11-651){ref-type="fig"}). Furthermore, a total of six studies involving 191 ECs and 262 precancerous lesions were included to evaluate the association between the methylation of *MLH1* in ECs and precancerous lesions. We observed that the methylation frequency of *MLH1* was markedly elevated in ECs compared with precancerous lesion samples (OR=3.08; 95% CI =1.64--5.92; *P*\<0.01; [Figure 2B](#f2-ott-11-651){ref-type="fig"}). The analysis of the association between *MLH1* methylation and esophageal precancerous lesions included 196 precancerous samples and 192 normal controls from five studies. As demonstrated in [Figure 2C](#f2-ott-11-651){ref-type="fig"}, the methylation frequency of *MLH1* was significantly higher in precancerous lesions than in controls (OR=3.75; 95% CI =1.08--13.02; *P*=0.04). The potential publication bias was assessed by Begg's funnel plot analysis and Egger's test. The results indicated no significant publication bias among the studies under analysis ([Figure 4](#f4-ott-11-651){ref-type="fig"}).

*MLH1* promoter methylation and clinicopathological features of EC patients
---------------------------------------------------------------------------

We also evaluated the association between *MLH1* methylation and clinicopathological features of EC patients, including age, gender, smoking behavior, alcohol consumption, differentiation grade, location, T stage, lymph node metastasis, distant metastasis, and clinical stage. Our analyses demonstrated that *MLH1* methylation was significantly associated with age (OR=1.79; 95% CI =1.20--2.66; *P*\<0.01), T grade (OR=3.7; 95% CI =2.37--5.77; *P*\<0.01), lymph node metastasis (OR=2.65; 95% CI =1.81--3.88; *P*\<0.01), distant metastasis (OR=7.60; 95% CI =1.23--47.19; *P*=0.03), and clinical stage (OR=4.46; 95% CI =2.88--6.91; *P*\<0.01). However, there was no correlation between *MLH1* promoter methylation and other clinicopathological characteristics of EC patients ([Table 3](#t3-ott-11-651){ref-type="table"}).

Prognostic value of *MLH1* promoter methylation for EC patients
---------------------------------------------------------------

A total of 207 EC patients from two studies[@b44-ott-11-651],[@b50-ott-11-651] were involved to assess the prognostic value of *MLH1* promoter methylation. The results revealed that *MLH1* methylation was significantly associated with poor OS of EC patients (HR =1.64; 95% CI =1.00--2.69; *P*\<0.05; [Figure 5](#f5-ott-11-651){ref-type="fig"}). More studies with larger sample sizes are necessary to further validate the prognostic value of *MLH1* promoter methylation in the future.

Diagnostic value of *MLH1* promoter methylation for EC patients
---------------------------------------------------------------

We further calculated the pooled sensitivity, specificity, and AUC and performed Fagan plot analysis from 15 case--control studies to evaluate the diagnostic value of *MLH1* promoter methylation for EC patients. The pooled sensitivity, specificity, and AUC values were 0.15 (95% CI =0.08--0.25), 0.99 (95% CI =0.97--1.00), and 0.77 (95% CI =0.73--0.81), respectively ([Figure 6](#f6-ott-11-651){ref-type="fig"}). As shown in [Figure 7](#f7-ott-11-651){ref-type="fig"}, the pretest probability values of being diagnosed with EC were defined as 25%, 50%, and 75%, respectively. The analysis demonstrated that the probabilities of a patient being diagnosed with EC were 89%, 96%, and 99%, respectively, if the *MLH1* promoter methylation detection result was positive. When the test was negative, the patient had a 22%, 46%, and 72% possibility of having EC, respectively.

Discussion
==========

EC is one of the most fatal digestive tract malignancies, representing the eighth leading cause of cancer-related deaths worldwide.[@b51-ott-11-651] Without effective early diagnosis biomarkers and therapeutic strategies, the prognosis of EC is relatively poor, with a 5-year survival rate of \<20%, although it may be variable in different histotypes.[@b52-ott-11-651] Aberrant DNA methylation in the TSG promoter has been identified as an important mechanism of tumorigenesis and progression of several cancers, including cervical cancer,[@b10-ott-11-651] oral cancer,[@b53-ott-11-651] and colorectal cancer.[@b54-ott-11-651] In addition, as a relatively early molecular change, aberrant methylation was reported to be a potential biomarker for early cancer diagnosis.[@b55-ott-11-651]

The *MLH1* gene is a critical component of the DNA MMR system and has been considered to play an essential role in maintaining genomic stability.[@b15-ott-11-651] Several previous studies evaluated whether *MLH1* promoter methylation is associated with EC risk, but the results of these studies were inconsistent because of the use of different histotypes, control types, population ethnicities, and detection methods.[@b40-ott-11-651],[@b45-ott-11-651] Therefore, we conducted a meta-analysis to assess the association between *MLH1* promoter methylation and EC carcinogenesis. The overall OR of *MLH1* promoter methylation frequency was higher in EC tissues than in control tissues, which is consistent with the results found for other types of carcinomas.[@b56-ott-11-651] The sensitivity analysis and the absence of heterogeneity indicate that our results were stable and credible. Moreover, the subgroup analysis based on ethnicity revealed that the OR of the association between *MLH1* methylation and EC was higher for Caucasian populations than for Asian populations, indicating that the Caucasian population may be more susceptible to *MLH1* promoter methylation. The majority of ECs can be subdivided into two main histological subtypes: adenocarcinomas and squamous cell carcinomas. Previous studies have demonstrated the molecular separation between ESCC and EAC, showing that ESCC has a stronger resemblance to head and neck squamous cell carcinoma than to EAC and that EAC more closely resembled gastric cancer than ESCC.[@b57-ott-11-651] In this study, the subgroup analysis of histology indicated that the OR of the EAC subgroup was greater than that of the ESCC subgroup, indicating that the methylated *MLH1* gene may be used to distinguish the histotype of EC. EC is a complicated and progressive disease. EAC originates predominantly from BE, and dysplasia is the precursor for both EAC and ESCC.[@b5-ott-11-651] Our analysis showed that the methylation level of the *MLH1* promoter was also significantly higher in EC than in premalignant lesions. Moreover, the frequency of *MLH1* methylation was markedly higher in premalignant lesions than in healthy controls. These results collectively indicate that hypermethylation of the *MLH1* promoter is involved in the onset and carcinogenesis of EC.

Furthermore, we evaluated the relationship between *MLH1* methylation and the clinicopathological parameters of EC. Age is believed to be an important cancer-related risk factor, and EC occurs mostly in patients aged \>50 years, with a median age of 68 years.[@b7-ott-11-651] Our findings revealed that *MLH1* promoter methylation was more likely to occur in elderly patients, which may account for the finding that patients aged \>60 years showed a rapid increase in EC.[@b7-ott-11-651] In addition, our analysis demonstrated that the frequency of *MLH1* promoter methylation was significantly elevated in advanced T grade, lymph node metastasis, distant metastasis, and advanced clinical stage EC patients, suggesting that *MLH1* promoter methylation may play a critical role in EC progression and metastasis. However, there was no correlation between *MLH1* promoter methylation and other clinicopathological characteristics of EC patients. We also investigated whether *MLH1* promoter hypermethylation was correlated with the prognosis of EC patients, based on the prediction of OS using multivariate analysis. The results revealed that compared with EC patients with *MLH1* promoter hypomethylation, those with *MLH1* promoter hypermethylation had a 1.64-fold higher risk of poor OS, indicating that hypermethylation of the *MLH1* promoter is a potential prognosis biomarker for EC patients. However, more studies are needed to confirm and further clarify this finding, as only 207 EC patients were analyzed in the present study.

Abnormal methylation biomarkers have proven to be useful in diagnosing numerous cancers.[@b58-ott-11-651],[@b59-ott-11-651] Hence, we evaluated the diagnostic effect of *MLH1* promoter methylation for EC based on 15 studies of EC versus healthy subjects. The *MLH1* methylation test exhibited a pooled sensitivity of 0.15, a specificity of 0.99, and an AUC of 0.77, indicating that *MLH1* promoter methylation has a moderate diagnostic accuracy for EC. *MLH1* promoter methylation alone may not be suitable for screening and diagnosing EC, due to its low sensitivity. However, given its near-perfect specificity, *MLH1* promoter methylation is a potential diagnostic biomarker for EC if combined with other diagnostic technologies, which we confirmed using Fagan plot analysis. The Fagan plot analysis demonstrated that if the pretest probabilities were assumed to be 25%, 50%, and 75%, then 89%, 96%, and 99% of patients would be correctly diagnosed with EC following positive *MLH1* methylation tests, suggesting that methylated *MLH1* has effective diagnostic power to distinguish EC patients from healthy individuals. More rigorously designed studies with larger sample sizes are essential to validate our findings.

However, there were several limitations of our meta-analysis that should be noted. First, only articles published in English and Chinese were included in the study, which may have contributed to selection bias. Second, most studies were conducted in Asian and Caucasian populations, while other ethnic groups, such as Africans, were underrepresented. Third, because there were relatively few studies describing the association between *MLH1* promoter methylation and clinicopathological parameters and OS, studies with larger sample sizes are needed to validate our findings. These studies should also be included in a future-updated meta-analysis to support the findings of the present study.

Conclusion
==========

This integrated analysis provided a strong evidence that *MLH1* methylation is significantly associated with the carcinogenesis, progression, and metastasis of EC. In addition, methylated *MLH1* is a promising biomarker for the diagnosis and prognosis of EC. Future research with larger sample sizes and strong study designs is essential to confirm our results.
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![Flow diagram of the selection process for this meta-analysis.](ott-11-651Fig1){#f1-ott-11-651}

###### 

Pooled forest plot of *MLH1* methylation frequency during the carcinogenesis of esophageal cancer.

**Notes:** (**A**) Carcinoma versus healthy controls: OR=8.40, 95% CI =5.75--12.28. (**B**) Carcinoma versus precancerous lesions: OR=3.08; 95% CI =1.64--5.92. (**C**) Precancerous lesions versus healthy controls: OR=3.75; 95% CI =1.08--13.02.

**Abbreviations:** *MLH1*, mutL homolog-1; OR, odds ratio.
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![Sensitivity analysis of pooled ORs for the association between *MLH1* methylation and esophageal cancer.\
**Abbreviations:** *MLH1*, mutL homolog-1; OR, odds ratio.](ott-11-651Fig3){#f3-ott-11-651}

![Begg's funnel plots and Egger's test of publication bias for *MLH1* methylation during the carcinogenesis of esophageal cancer.\
**Notes:** (**A**) Carcinoma versus healthy controls: Begg's test: *P*=0.69; Egger's test: *P*=0.29. (**B**) Carcinoma versus precancerous lesions: Begg's test: *P*=0.42; Egger's test: *P*=0.52. (**C**) Precancerous lesions versus healthy controls: Begg's test: *P*=0.81; Egger's test: *P*=0.53.\
**Abbreviations:** EC, esophageal cancer; *MLH1*, mutL homolog-1; NC, normal control; PC, precancerous lesions.](ott-11-651Fig4){#f4-ott-11-651}

![Forest plot for pooled HR and the corresponding 95% CI of *MLH1* methylation for OS of EC patients.\
**Abbreviations:** EC, esophageal cancer; HR, hazard ratio; *MLH1*, mutL homolog-1; OR, odds ratio; OS, overall survival.](ott-11-651Fig5){#f5-ott-11-651}

![SROC plots of methylated *MLH1* for the diagnosis of esophageal cancer.\
**Abbreviations:** *MLH1*, mutL homolog-1; SENS, sensitivity; SPEC, specificity; SROC, summary of receiver operating characteristic.](ott-11-651Fig6){#f6-ott-11-651}

![Fagan plot analysis to evaluate the diagnostic power of methylated *MLH1* for esophageal cancer.\
**Notes:** (**A**) The posttest probability was 89% at a pretest probability of 25%. (**B**) The posttest probability was 96% at a pretest probability of 50%. (**C**) The posttest probability was 99% at a pretest probability of 75%.\
**Abbreviations:** LR, likelihood ratio; *MLH1*, mutL homolog-1.](ott-11-651Fig7){#f7-ott-11-651}

###### 

The basic characteristics of all eligible studies

  -------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Year   Country       Ethnicity   Method   Carcinoma   Normal   Precarcinoma   NOS                    
  ---------------------------------- ------ ------------- ----------- -------- ----------- -------- -------------- ------ ---- ---- ----- ---
  Eads et al[@b33-ott-11-651]        2001   USA           Caucasian   qMSP     2           22       0              31     A    1    19    7

  Nie et al[@b34-ott-11-651]         2002   China         Asian       MSP      5           21       0              25     A    2    13    7

  Geddert et al[@b35-ott-11-651]     2004   Germany       Caucasian   MSP      7           50       0              50     A    NA   NA    8

  Tzao et al[@b36-ott-11-651]        2005   China         Asian       MSP      37          60       0              20     A    NA   NA    7

  Clement et al[@b37-ott-11-651]     2006   Switzerland   Caucasian   MS-DBA   1           27       0              16     H    NA   NA    7

  Guo et al[@b38-ott-11-651]         2006   China         Asian       MSP      16          69       1              17     H    8    60    7

  Ishii et al[@b39-ott-11-651]       2007   Japan         Asian       COBRA    6           56       1\             56\    A\   0    21    8
                                                                                                    0              42     H               

  Wang et al[@b40-ott-11-651]        2008   China         Asian       MSP      4           125      0\             125\   A\   NA   NA    8
                                                                                                    0              10     H               

  Liao et al[@b41-ott-11-651]        2009   China         Asian       MSP      22          105      2              105    A    NA   NA    7

  Moriichi et al[@b42-ott-11-651]    2009   Japan         Asian       MSP      NA          NA       0              21     NA   7    83    7

  Vasavi et al[@b43-ott-11-651]      2010   India         African     MSRE     33          50       NA             NA     NA   NA   NA    8

  Lu et al[@b44-ott-11-651]          2011   China         Asian       MSP      4           120      0              120    A    NA   NA    8

  Ling et al[@b45-ott-11-651]        2011   China         Asian       qMSP     102         235      21             235    A    NA   NA    8

  Wang et al[@b46-ott-11-651]        2011   China         Asian       MSRE     1           13       0              55     H    0    21    7

  Chen et al[@b47-ott-11-651]        2012   China         Asian       MSP      11          257      0              257    A    NA   NA    8

  Su et al[@b22-ott-11-651]          2014   China         Asian       MSP      9           51       6              51     A    NA   NA    8

  Fukui et al[@b48-ott-11-651]       2016   Japan         Asian       MS-HRM   8           10       NA             NA     NA   29   128   8

  Guilleret et al[@b49-ott-11-651]   2016   Switzerland   Caucasian   MLM      17          26       0              8      H    NA   NA    7

  Wu et al[@b50-ott-11-651]          2017   China         Asian       MSP      53          87       NA             NA     NA   NA   NA    8
  -------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** A, autologous (control samples from the same patients); COBRA, combined bisulfite restriction analysis; H, heterogeneous (control samples from other individuals); M+, positive for *MLH1* methylation test; *MLH1*, mutL homolog-1; MLM, methylation ligation-dependent macroarray; MS-DBA, methylation-sensitive dot-blot assay; MS-HRM, methylation-sensitive high-resolution melting analyses; MSP, methylation-specific polymerase chain reaction; MSRE, methylation-sensitive restriction endonuclease; NA, not available; NOS, Newcastle--Ottawa Scale; qMSP, quantitative methylation-specific polymerase chain reaction.

###### 

Subgroup analyses of *MLH1* promoter methylation in esophageal cancer

  --------------------------------------------------------------------------------------------------------
  Subgroup         Case   Control   Pooled\       *P*-value   Heterogeneity                         
                                    OR (95% CI)                                                     
  ---------------- ------ --------- ------------- ----------- --------------------- -------- ------ ------
  Ethnicity                                                                                         

   Caucasian       27     125       0             105         11.90 (2.75--51.51)   \<0.01   0      0.62

   Asian           217    1,112     31            1,118       8.15 (5.75--12.08)    \<0.01   16.2   0.29

  Histology                                                                                         

   ESCC            224    1,162     31            1,168       8.32 (5.64--12.29)    \<0.01   10.6   0.34

   EAC             20     75        0             55          9.98 (1.83--54.32)    \<0.01   0      0.45

  Control source                                                                                    

   Autologous      209    1,102     30            1,075       8.28 (5.58--12.29)    \<0.01   15.9   0.29

   Heterogeneous   28     290       1             140         6.54 (2.12--11.69)    \<0.01   0      0.55

  Methods                                                                                           

   MSP             115    858       9             780         8.61 (4.64--15.97)    \<0.01   0      0.88

   No MSP          129    379       22            443         8.25 (5.12--13.30)    \<0.01   34.7   0.14

  Sample size                                                                                       

    \<60           48     266       7             334         5.59 (2.74--11.39)    \<0.01   17     0.3

    ≥60            196    971       24            889         9.74 (6.21--15.27)    \<0.01   0      0.75

  Published year                                                                                    

    \<2010         100    535       4             497         12.74 (5.84--27.78)   \<0.01   0      0.89

    ≥2010          144    702       27            726         6.99 (4.52--10.82)    \<0.01   42.9   0.12
  --------------------------------------------------------------------------------------------------------

**Abbreviations:** EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; M+, positive for *MLH1* methylation test; *MLH1*, mutL homolog-1; MSP, methylation-specific polymerase chain reaction; OR, odds ratio.

###### 

Association between *MLH1* promoter methylation and clinicopathological features of esophageal cancer patients

  ---------------------------------------------------------------------------------------------------------------
  Characteristics         No   Case/control             Pooled\              *P*-value   Heterogeneity   
                                                        OR (95% CI)                                      
  ----------------------- ---- ------------------------ -------------------- ----------- --------------- --------
  Age                     4    Older/younger            1.79 (1.20--2.66)    \<0.01      0               0.4

  Gender                  4    Male/female              1.12 (0.61--2.05)    0.71        0               0.99

  Smoking behavior        3    Yes/no                   0.90 (0.46--1.74)    0.75        0               0.78

  Alcohol consumption     3    Yes/no                   0.81 (0.42--1.57)    0.54        0               0.73

  Differentiation grade   4    Poor/well and moderate   1.45 (0.92--2.28)    0.11        26.7            0.25

  Location                4    Up and middle/down       0.87 (0.58--1.31)    0.5         0               0.9

  T stage                 6    T~3+4~/T~1+2~            3.7 (2.37--5.77)     \<0.01      78.8            \<0.01

  Lymph node metastasis   6    Yes/no                   2.65 (1.81--3.88)    \<0.01      73.2            \<0.01

  Distant metastasis      4    Yes/no                   7.60 (1.23--47.19)   0.03        63.6            0.04

  Clinical stage          4    III + IV/I + II          4.46 (2.88--6.91)    \<0.01      88.9            \<0.01
  ---------------------------------------------------------------------------------------------------------------

**Abbreviations:** *MLH1*, mutL homolog-1; No, number of studies; OR, odds ratio.
